



Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies

Christian Ferschmann · Konstantin Messerschmidt · Johannes Gnörich · Henryk Barthel · Ken Marek · Carla Palleis, et al. [full author details at the end of the article]

Received: 11 July 2023 / Accepted: 4 February 2024 / Published online: 17 February 2024
© The Author(s) 2024

Abstract

Purpose We hypothesized that severe tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlate with more severe striatal dopamine deficiency in four-repeat (4R) tauopathies. Therefore, we correlated [¹⁸F]PI-2620 tau-positron-emission-tomography (PET) imaging with [¹²³I]-Ioflupane single-photon-emission-computed tomography (SPECT) for dopamine transporter (DaT) availability.

Methods Thirty-eight patients with clinically diagnosed 4R-tauopathies (21 male; 69.0 ± 8.5 years) and 15 patients with clinically diagnosed α-synucleinopathies (8 male; 66.1 ± 10.3 years) who underwent [¹⁸F]PI-2620 tau-PET and DaT-SPECT imaging with a time gap of 3 ± 5 months were evaluated. Regional Tau-PET signals and DaT availability as well as their

Christian Ferschmann and Konstantin Messerschmidt contributed equally.

German Imaging Initiative for Tauopathies (GI4T) LMU Munich, Dept. Neurology: Günter Höglinger, Johannes Levin, Jonathan Vöglein, Urban Fietzek, Sonja Schönecker, Georg Nübling, Catharina Prix, Adrian Danek, Carla Palleis, Endy Weidinger, Sabrina Katzdobler, Anna Stockbauer

LMU Munich, Dept. Nuclear Medicine: Matthias Brendel, Mengmeng Song, Gloria Biechele, Anika Finze, Leonie Beyer, Peter Bartenstein, Florian Eckenweber, Simon Lindner, Franz-Joseph Gildehaus, Emanuel Joseph, Maximilian Scheifele, Christian Zach, Johannes Gnörich, Mirlind Zaganjori

LMU Munich, Dept. Psychiatry and Psychotherapy: Robert Perneczky, Jan Häckert

LMU Munich, Dept. Radiology: Boris-Stephan Rauchmann, Sophia Stöcklein

University of Leipzig, Dept. Nuclear Medicine: Henryk Barthel, Marianne Patt, Andreas Schildan, Osama Sabri, Michael Rullmann

University of Leipzig, Dept. of Neurology: Joseph Classen, Dorothee Saur, Jost-Julian Rumpf

Max Plank Institute for Human Cognitive and Brain Sciences Leipzig: Matthias L. Schroeter

University of Cologne, Dept. Nuclear Medicine and Forschungszentrum Jülich: Alexander Drzezga, Thilo van Eimeren, Jochen Hammes, Bernd Neumaier

University of Cologne, Dept. Neurology: Michael T. Barbe, Oezguer Onur

DZNE Munich/Bonn: Estrella Morenas-Rodriguez, Jochen Herms, Sigrun Roeber, Thomas Arzberger, Christian Haass, Frank Jessen

Life Molecular Imaging: Andrew Stephens, Norman Koglin, Andre Mueller

principal components were correlated in patients with 4R-tauopathies and α -synucleinopathies. Both biomarkers and the residuals of their association were correlated with clinical severity scores in 4R-tauopathies.

Results In patients with 4R-tauopathies, [^{18}F]PI-2620 binding in basal ganglia and midbrain regions was negatively associated with striatal DaT availability (i.e. globus pallidus internus and putamen ($\beta = -0.464$, $p = 0.006$, Durbin-Watson statistics = 1.824) in a multiple regression model. Contrarily, [^{18}F]PI-2620 binding in the dentate nucleus showed no significant regression factor with DaT availability in the striatum ($\beta = 0.078$, $p = 0.662$, Durbin-Watson statistics = 1.686). Patients with α -synucleinopathies did not indicate any regional associations between [^{18}F]PI-2620-binding and DaT availability. Higher DaT-SPECT binding relative to tau burden was associated with better clinical performance ($\beta = -0.522$, $p = 0.011$, Durbin-Watson statistics = 2.663) in patients with 4R-tauopathies.

Conclusion Tau burden in brain regions involved in dopaminergic pathways is associated with aggravated dopaminergic dysfunction in patients with clinically diagnosed primary tauopathies. The ability to sustain dopamine transmission despite tau accumulation may preserve motor function.

Keywords 4R-Tau · DaT imaging · [^{18}F]PI-2620 tau-PET · Motor reserve

Background

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are primary tauopathies that belong to the spectrum of atypical parkinsonian syndromes. While neurodegenerative parkinsonian syndromes (i.e. Parkinson's disease (PD) and atypical parkinsonian disorders) jointly show a loss of function in the dopaminergic system, PSP and CBD are histopathologically distinct compared to α -synucleinopathies such as PD and multiple systems atrophy (MSA). The key histopathological features in PSP and CBD are pathological neuronal and glial cell inclusions of the four-repeat (4R)-tau isoform [1–3]. 4R-tau pathology plays a key role in neuronal dysfunction and its accumulation in PSP and CBD is thought to follow specific spatiotemporal patterns, initially accumulating in the brainstem and subcortical areas followed by cortical deposition in later disease stages [4–7]. There is growing evidence that the spreading of tau in neurodegenerative disorders occurs in a prion-like manner into anatomically and functionally connected regions of the brain thereby enabling disease progression [8–12]. Yet the connection between pathological tau accumulation and loss of dopaminergic cells in 4R-tauopathies remains poorly understood. In this study, we aimed to elucidate the association between tau pathology and dopaminergic loss using [^{18}F]PI-2620 tau-positron-emission-tomography (PET) and [^{123}I]Ioflupane single-photon-emission-computed tomography (SPECT) imaging in the same individuals in vivo. Using PET radiotracers, imaging of tau deposits has become feasible lately and second generation tau-PET tracers such as [^{18}F]PI-2620 [13] and [^{18}F]PM-PBB3 [14] provide new possibilities to detect not only 3/4R-tau depositions typically found in Alzheimer's disease (AD) but also have affinity to 4R-tau. Our consortium showed autoradiography binding to PSP tissue in vitro

and discrimination of patients with PSP and corticobasal syndrome (CBS) from controls in vivo using [^{18}F]PI-2620 [15–18]. Others were successful to show in vitro binding and differentiation of 4R-tauopathies from controls in vivo using [^{18}F]PM-PBB3 [14, 19, 20]. [^{123}I]Ioflupane on the other hand is a well-established SPECT ligand for in vivo imaging of the dopaminergic system with a high affinity to the striatal presynaptic dopamine transporter (DaT)[21]. In a clinical setting, [^{123}I]Ioflupane SPECT imaging is frequently used to differentiate degenerative parkinsonian disorders from non-degenerative parkinsonism (e.g. vascular, toxic, drug-induced) as well as to distinguish Dementia with Lewy bodies (DLB) from AD [22, 23]. Using [^{18}F]PI-2620 tau-PET, we hypothesized that high tau burden in brain regions involved in direct or indirect pathways of the basal ganglia correlates with a more severe loss of DaT availability visualized by [^{123}I]Ioflupane SPECT imaging.

Methods

Study design and patient selection

Thirty-eight patients with a clinically diagnosed 4R-tauopathy [PSP with Richardson syndrome (PSP-RS) and CBD with corticobasal syndrome phenotype (CBD-CBS)] were examined in comparison to a group of 15 patients with assumed α -synucleinopathies [Parkinson's disease (PD), multiple systems atrophy (MSA), DLB] in this combined tau-PET and DaT-SPECT study.

Patients with 4R-tauopathies according to current diagnostic criteria [24] were recruited from three different centers: Munich, Leipzig and New Haven (25 cases from the LMU University Hospital of Munich, 9 cases from Leipzig and 4 cases from New Haven). The 4R-tauopathy group

(age: 69.0 ± 8.5 years, 21 male) consisted of 26 patients with PSP-RS (PSP rating scale: 36.9 ± 13.8), 12 fulfilling criteria for CBD-CBS (PSP rating scale: 36.0 ± 11.7). Patients with clinically diagnosed α -synucleinopathies (age: 66.1 ± 10.3 years, 8 male) consisted of 13 cases from Munich and two cases from Leipzig, characterized by 10 patients with PD, three patients with MSA, two patients with DLB. Both groups were evaluated by dual imaging of [^{18}F]PI-2620 tau-PET and [^{123}I]-Ioflupane SPECT. The two scans were performed with a time gap of 3 ± 5 months and a maximum allowed time gap of 2 years.

To quantify the tau-PET scans, z-scores were calculated against an age-matched cognitively healthy control group consisting of 23 individuals from three different centers in Munich ($n = 10$), New Haven ($n = 8$) and Melbourne ($n = 5$).

Patients from Munich are part of the observational study registered at the German Clinical Trials Register (DRKS00016920) and the tau-PET data from these patients were partly published elsewhere [15, 18]. All participants provided written informed consent for PET imaging. The study protocol as well as PET data analyses were approved by the local ethics committee of LMU of Munich (application numbers 17–569 and 19–022). The study was carried out according to the principles of the Helsinki Declaration.

[^{18}F]PI-2620 tau-PET and [^{123}I]-Ioflupane DaT-SPECT imaging

Radiosynthesis

Radiosynthesis of [^{18}F]PI-2620 was achieved by nucleophilic substitution on a BOC-protected nitro precursor using an automated synthesis module (IBA Synthera, Louvain-la-neuve, Belgium). The protecting group was cleaved under the radiolabelling conditions. The product was purified by semipreparative HPLC. Radiochemical purity was 99%. Non-decay yields were about 35% with a molar activity of $3 \cdot 10^6$ GBq/mmol at the end of synthesis. [^{123}I]-Ioflupane was purchased from GE healthcare.

Dynamic [^{18}F]PI-2620 tau-PET acquisition and reconstruction

The cohort of this study underwent scanning in a full dynamic setting (0–60 min p.i.) on two different scanners at the Department of Nuclear Medicine, LMU Munich, either a Biograph 64 or a Siemens mCT PET/CT scanner (both Siemens, Erlangen, Germany), on a Siemens ECAT EXACT HR + camera at MNI, on a Siemens Biograph mMR (Siemens, Erlangen, Germany) in Leipzig and on a Philips Gemini TF 64 PET/CT (Eindhoven, The Netherlands) in Melbourne. Details on all scanners, as well as acquisition and reconstruction parameter are provided in the Supplement of

our previous study [15]. The intravenous injected bolus dose was 168 to 334 MBq and was followed by a 10 ml saline flush [25]. Continuous brain imaging started right after the injection, divided into a series of 23 frames (6×30 s, 4×60 s, 4×120 s, and 9×300 s). Before processing, all dynamic images underwent correction for head motion or non-standard posture (i.e. excessive head hypokinesia), in case they did not pass a visual check. A single 20–40 min frame was summed and analyzed after motion correction [25].

DaT-SPECT image acquisition and reconstruction

In order to protect against irradiation of the thyroid, the subjects were pretreated with perchlorate at 30–60 min before intravenous injection of a mean 145 ± 7 MBq [^{123}I]-Ioflupane as a single bolus. Single frame SPECT emission recordings of 30 min duration were recorded at four hours after tracer injection using a triple-headed gamma camera (Picker Prism3000, Cleveland, OH) equipped with low-energy, high-resolution fan beam collimators. The acquisition parameters consisted of a rotational radius of 12.7–13.0 cm, a 20% energy window centered on 159 keV, 120 projection angles over 360° (60 s per projection), and a 128×128 matrix. Images were reconstructed by filtered back-projection (low-pass filter with a cut-off frequency of 0.27 Nyquist, fifth order) and corrected for attenuation according to Chang ($\mu = 0.12 \text{ cm}^{-1}$). Final voxel size in the reconstructed and reoriented images was $2.26 \times 2.26 \times 3.56$ mm.

Tau-PET data analysis

All image data were processed and analyzed with PMOD (Version 3.4, PMOD Technologies Ltd., Zurich, Switzerland). Late phase 20–40 min [^{18}F]PI-2620 PET images were coregistered to the Montreal Neurology Institute (MNI) space using a non-linear transformation (brain normalization settings: nonlinear warping, 8 mm input smoothing, equal modality, 16 iterations, frequency cutoff 3, regularization 1.0, no thresholding) [26]. Standardized uptake value ratios (SUVr) were generated by dividing the 20–40 min static [^{18}F]PI-2620 PET images through a cerebellar reference region, excluding the dentate nucleus, the cerebellar white matter and superior and posterior layers [15]. SUVr were extracted from 13 PSP target regions of interest in the MNI space: bilateral putamen, bilateral globus pallidus (internal and external part), bilateral subthalamic nucleus, bilateral substantia nigra, dorsal midbrain, bilateral dentate nucleus while keeping in mind that substantia nigra generally shows a higher background signal possibly due to additional neuromelanin off-target binding [15]. Tau-PET z-scores were calculated against the age-matched cognitively healthy control group.

DaT-SPECT data analysis

The DaT-SPECT scans were examined as DICOM files by using Hermes BRASS (Hermes Medical Solutions, Stockholm, Sweden) with the occipital lobe as the reference region (BRASS model 5 and BRASS model 7). Caudate nucleus, anterior putamen and posterior putamen served as target regions (all bilateral) and z-scores against healthy controls with correction for age were calculated [27]. DaT-SPECT data of one patient from New Haven had to be evaluated with manual created VOIs fitting to the selected areas by using PMOD (Version 3.4, PMOD Technologies Ltd., Zurich, Switzerland) due to failed coregistration to the template of the software package.

Statistics

The statistical analyses were performed using SPSS (version 26.0, Armonk, New York, USA) and Excel (Microsoft, Redmond, WA, USA). Statistical significance was defined at a level of $p < 0.05$ in all analyses. The data showed as $n \pm x$ represent the average and the standard deviation. Tau-PET and DaT-SPECT z-scores were normally distributed, as assessed by the Kolmogorov–Smirnov-test, $p > 0.05$. *T*-tests and X^2 tests were performed to compare demographics between patients with 4R-tauopathies and patients with α -synucleinopathies. One-way analysis of variance with age, gender and center as covariates (ANCOVA) was performed for comparison of tau-PET and DaT-SPECT SUVr and z-scores including p value and η^2 as a measure of effect size.

We calculated a multiple regression analysis including the two biomarkers as well as age, gender and center as covariates in all target regions. The Durbin-Watson statistics of all regression models performed in this study provided a value close to 2.0, which showed that the residuals were independent and not inter-correlated. We performed a principal component analysis (PCA) for each of the two biomarkers concerning all target regions in order to achieve a dimensional reduction of the data to its essential features while mitigating possible effects of multileg testing. Subsequently, we performed a multiple regression analysis including the calculated components. The Kaiser-Mayer-Olkin (KMO) measure for sampling adequacy and Bartlett's test of sphericity showed that the data was suitable for data-driven dimension reduction.

To assess potential motor reserve effects, we performed a multiple regression analysis including the residuals of the Tau/DaT regression model and PSP rating scale scores. Moreover, the PSP rating scale was differentiated between items that cover motor and cognition function, which then were included in a separate multiple regression model.

Results

Demographics

A total of 38 patients with 4R-tauopathies and 15 patients with α -synucleinopathies were included in the analysis (Supplementary Table 1). Patients with 4R-tauopathies did not differ in age (69.0 ± 8.5 years vs. 66.1 ± 10.3 years; $p = 0.21$; *t*-test) and gender (55% male vs. 53% male; $p = 0.899$; X^2 test) from patients with α -synucleinopathies. Patients with 4R-tauopathies showed a mean disease duration of 26.2 ± 16.6 months compared to a mean disease duration of 15.6 ± 10.6 months in patients with α -synucleinopathies ($p = 0.27$; *t*-test).

[¹⁸F]PI-2620 tau-PET and [¹²³I]-Ioflupane DaT-SPECT binding

As expected from previous studies [15, 18], higher [¹⁸F]PI-2620 signal was observed all 13 target regions of patients with 4R-tauopathies when compared to patients with α -synucleinopathies (Fig. 1a, Supplementary Table 2). Strongest regional [¹⁸F]PI-2620 signal differences between patients with 4R-tauopathies and patients with α -synucleinopathies were observed in the right globus pallidus internus (SUVr: 1.47 ± 0.27 vs 1.27 ± 0.14 ; $p = 0.028$, ANCOVA controlled for age, gender and center). 63.2% of patients with 4R-tauopathies and 6.7% of patients with α -synucleinopathies ($p < 0.001$; X^2 test) showed at least one [¹⁸F]PI-2620 positive target region (z-score > 2). In regard to the SN the right SN showed a significantly higher signal in 4R patients than in α -synucleinopathies while there was no significant difference to HC (SUVr: 1.36 ± 0.20 vs 1.24 ± 0.11 α -syn vs 1.32 ± 0.12 HC; $p(\alpha$ -syn): 0.04, $p(\text{HC})$: 0.50; ANCOVA controlled for age, gender and center). Quantitative DaT-SPECT showed similar dopamine deficiency in patients with 4R-tauopathies compared to patients with α -synucleinopathies (Fig. 1b, Supplementary Table 3). DaT-SPECT binding in at least one target region was significantly reduced (z-score < -2) in 89.5% of patients with 4R-tauopathies and in 86.7% of patients with α -synucleinopathies ($p < 0.001$; X^2 test). Figure 1c visualizes Tau-PET SUVr and DaT-SPECT ratio images of the group average of patients with 4R-tauopathies versus α -synucleinopathies.

Regional associations between tau burden and DaT availability

In patients with 4R-tauopathies, several negative associations were observed between regional tau-PET signal




Fig. 1 Quantitative tau-PET and DaT-SPECT comparison of patients with clinical diagnosis of 4R-tauopathies (4RT) and α -synucleinopathies (α -syn). **A** Z-score distribution of tau-PET including p-value and effect size η^2 in representative brain regions of patients with 4R-tauopathies and patients with α -synucleinopathies. SUVR=standardized uptake value ratio. **B** Z-score distribution of

DaT-SPECT including p-value and effect size η^2 in comparison of patients with 4R-tauopathies and patients with α -synucleinopathies. **C** Tau-PET SUVR and DaT-SPECT ratio images show the group average of patients with clinically diagnosed 4R-tauopathies and clinically diagnosed α -synucleinopathies

and DaT-SPECT binding in the basal ganglia in a multiple regressions model including age, gender and center (Fig. 2a). Contrary, there was no significant association between tau-PET and DaT-SPECT quantification in patients with α -synucleinopathies (Fig. 2a). As an example, tau-PET signal in the right globus pallidus internus showed the strongest negative regression factor with DaT availability in the right posterior putamen of patients with 4R-tauopathies

($\beta = -0.464, p = 0.006$, Durbin-Watson statistics = 1.824; Fig. 2c), whereas this association was not observed in patients with α -synucleinopathies ($\beta = -0.178, p = 0.637$, Durbin-Watson statistics = 1.810; Fig. 2c). As a negative control region without striatal projection, tau-PET binding in the dentate nucleus was not associated with DaT-SPECT loss in both patient populations (Fig. 2a). Due to asymmetrical and higher DaT loss on the left hemisphere in our patient




Fig. 2 Regional associations between tau-PET and DaT-SPECT in patients with 4R-tauopathies (4RT) and α -synucleinopathies (α -syn). **A** Heat maps show regional associations between tau-PET (y-axis) and DaT-SPECT (x-axis). Significant associations providing a p value < 0.05 are indicated with *. Blue colors indicate negative multiple regression coefficients (β). Orange colors indicate positive multiple regression coefficients (β). Regions analyzed for tau-PET: putamen right, left (PUT r/l), globus pallidus externus right, left (GPe r/l), globus pallidus internus right, left (GPi r/l), subthalamic nucleus right, left (STN r/l), substantia nigra (SN r/l), dorsal midbrain (DMB) and dentate nucleus right, left (Dentate r/l). Regions analyzed for

DaT-SPECT: caudate right, left, anterior putamen right, left (aPUT r/l) and posterior putamen right, left (pPUT r/l). **B** The scheme shows the basic idea of the connection between high tau burden in brain regions involved in direct or indirect pathways of the basal ganglia and striatal dopaminergic loss. Arrow thickness shows the level of correlation of the examined regions for patients with 4R-tauopathies, whereas no significant correlations were found in α -synucleinopathies (dashed lines). **C** Linear correlation between tau burden in the globus pallidus internus and the DaT availability in the posterior putamen of the right hemisphere

group, we also examined regional associations focused on the more affected side of each patient, which showed a similar negative association (Supplementary Fig. 1). A schematic visualization of the connection between brain regions with high tau burden and striatal dopaminergic loss is given in Fig. 2b.

Data-driven tau-PET and DaT-SPECT correlation

To achieve a dimensional reduction, we performed a data-driven principal component analysis (PCA) using all target

regions for each of the two biomarkers. The PCA comprised two principal components for [18 F]PI-2620 target regions (Kaiser Mayer Olkin criteria: 0.805, Bartlett's test on sphericity: $p < 0.001$; accounted variance for the two components: 72.38%, 11.15%; Fig. 3a, b, Supplementary Table 4) and one principal component for DaT-SPECT target regions (Kaiser Mayer Olkin criteria: 0.829, Bartlett's test on sphericity: $p < 0.001$, accounted variance for the component: 88.2%; Supplementary Table 5). Principal component 1 of tau-PET (nigrostriatal pathway regions) was associated in the multiple regression analysis with the principal




Fig. 3 Data driven correlation between tau burden and DaT availability. **A** Visualization of the brain regions resulting from the principal component analysis of tau-PET target regions. The color bar indicates corresponding loading values. Two principal components emerged, consisting of putamen, globus pallidus, subthalamic nucleus and the substantia nigra (principal component 1) as well as dentate nucleus and dorsal midbrain (principal component 2). **B** Visualized values of

the rotated component matrix derived from the principal component analysis. **C** Tau-PET principal component 1 (tau-PET PC1) indicated a significant negative association with the DaT-SPECT principal component (DaT-SPECT PC), whereas tau-PET principal component 2 (tau-PET PC2) was not associated with the DaT-SPECT PC in a multiple regression model

component of DaT-SPECT using age, gender and center as covariates ($\beta = -0.442, p = 0.015$, Durbin-Watson statistics = 2.270; Fig. 3c). There was no association between principal component 2 of tau-PET (dentate nucleus and dorsal midbrain) and the principal component of DaT-SPECT ($\beta = 0.105, p = 0.572$, Durbin-Watson statistics = 2.084; Fig. 3c).

Preserved DaT availability relative to tau burden suggests concept of a motor reserve in patients with 4RT

Finally, we explored the associations between both biomarkers and clinical severity in patients with 4R-tauopathies. The principal components 1 and 2 of tau-PET did not indicate an association with the PSP rating (PC1: $\beta = -0.016, p = 0.944$,

Durbin-Watson statistics = 2.492/ PC2: $\beta = -0.190, p = 0.401$, Durbin-Watson statistics = 2.491), whereas the principal component of DaT-SPECT showed a significant negative association with the PSP rating scale in a multiple regression analysis with age, gender and center as covariates ($\beta = -0.512, p = 0.013$, Durbin-Watson statistics = 2.877). To investigate potential reserve mechanisms, we tested for an association between the residuals resulting from the regression analysis of tau-PET and DaT-SPECT with the PSP rating scale, PSP rating scale items for motor function and items for mentation as well as the Montreal Cognitive Assessment (MOCA) score separately (Supplementary Table 6). PSP rating scale single item scores as well as MOCA scores were only available for patients from Munich. Interestingly, we observed a significant negative association between the residuals resulting from the

tau-PET/DaT-SPECT association and the PSP rating scale in the multiple regression ($\beta = -0.522$, $p = 0.011$, Durbin-Watson statistics = 2.663; Fig. 4a). Preserved clinical performance was also observed in individual patients with 4R-tauopathies and high tau burden but sustained dopamine transporter availability (Fig. 4b), speaking for a variable vulnerability of dopaminergic neurons in presence of 4R tau. Furthermore, the regression model between the residuals and PSP rating scale motor function items showed an even stronger significant association ($\beta = -0.590$, $p = 0.019$,

Durbin-Watson statistics = 2.319; Fig. 5), whereas items that represent mentation or the Montreal Cognitive Assessment Score did not provide a significant regression model (Mentation items: $\beta = -0.302$, $p = 0.214$, Durbin-Watson statistics = 2.070; Fig. 5/ MOCA: $\beta = 0.180$, $p = 0.408$, Durbin-Watson statistics = 1.392).

To analyze which factor, tau burden, DaT loss or the combination of both, is the best regressor to explain symptoms of the PSP rating scale subsets, we performed a two-way interaction multiple regression analysis. The strongest




Fig. 4 Preserved DaT availability relative to tau burden suggests concept of a motor reserve in patients with 4RT. **A** Residuals of the linear regression between the tau-PET principal component 1 (tau-PET PC1) and the DaT-SPECT principal component (DaT-SPECT PC) positive (green) and negative (red) were obtained as an index of preserved DaT availability despite tau burden. Preserved DaT availability was associated with lower disease severity in the PSP rating scale (right panel). Only patients with PSP rating scale scores are depicted.

B Exemplary patients with 4R-tauopathies showing high tau burden, preserved DaT availability and mild clinical severity (upper row, 73y, female, PSP-CBS, PSP rating scale: 26) as well as moderate tau burden, strongly decreased DaT availability and severe clinical deterioration (lower row, 79y, female, PSP-CBS, PSP rating scale: 49). Axial slices show individual tau-PET z-scores on a standard MRI-template in contrast against healthy controls and individual DaT SPECT ratio images




Fig. 5 Comparison PSP rating scale items for motor function and mentation. Preserved DaT availability was associated with lower disease severity in the PSP rating scale scores for motor function (left panel), while there was no significant association between preserved

DaT availability and lower disease severity in the PSP rating scale scores for mentation (right panel). Only patients with PSP rating scale scores for motor function and mentation items are depicted

significant regression factor for motor function items was accounted by the principal component of DaT-SPECT (Supplementary Table 7).

Discussion

We present the first study using the second generation tau-PET tracer [^{18}F]PI-2620 to investigate associations between tau pathology and dopaminergic loss in the striatum of patients with 4R-tauopathies. We demonstrate *in vivo* that a high tau burden in brain regions involved in direct or indirect pathways of the basal ganglia of patients with 4R-tauopathies is associated with aggravated loss of DaT availability in the striatum as visualized by [^{123}I]-Ioflupane SPECT, supporting the role of tau pathology as a potential driver for dopaminergic dysfunction. Regarding dopaminergic functioning, our data show that preserved DaT-SPECT binding relative to the individual tau load was associated with better clinical performance. This highlights the potential of combined tau-PET and DaT-SPECT imaging to detect patients with a high motor reserve due to sustained dopaminergic transmission relative to 4R tau burden.

4R-tau is the key neuropathological feature in PSP and CBD which both show a broad spectrum of cognitive and motor symptoms [24, 28]. *Post mortem* studies revealed that distribution and burden of tau pathology is closely related to different phenotypical subtypes [4, 28, 29]. In this regard, first generation tau-PET tracers such as [^{18}F]AV-1451 showed a good correlation between autopsy confirmed cases and of tracer uptake [30–32]. In a recent post mortem tracer binding study of second generation tau tracers [^{18}F]PI-2620, [^{18}F]MK-6240 and [^{18}F]RO-948 in AD, PSP and CBD patients all tracers showed similar binding patterns

in AD while only [^{18}F]PI-2620 showed a high specificity for PSP and CBD tau pathology [33] highlighting its diagnostic utility for detecting 4R-tau. In addition, a recent *in silico* study confirms that among the second-generation tau-tracers PI-2620, PM-BB3 and CBD-2115 bind to 4R-tau [34]. [^{18}F]PM-PBB3 also showed high binding affinity to 4R-tau but binding in clinically diagnosed patients with MSA [35]. So far, the availability of PET-tracers binding to 4R-tau is very limited and further development and utilization of specific 4R-tau PET tracers are warranted.

Regarding the regional associations of tau-PET signal in typical target regions of tau accumulation in 4R-tauopathies and striatal DaT binding, we found that only regions of the nigrostriatal pathway and regions involved in direct or indirect pathways of the basal ganglia revealed a significant negative correlation between tau-PET and DaT-SPECT (Fig. 2). The close association between tau deposition within the dopaminergic system and its loss of function supports the view that tau related toxicity reacts as a driver in the degeneration/dysfunction of dopaminergic cells. Second, the correlation of tau deposition within a functionally highly connected system and its loss of function strengthens the concept of interneuronal tau propagation which states that tau is transmitted via synaptic and extrasynaptic pathways while the transmission is enhanced by neuronal activity [12, 36–38]. This concept was also underpinned by our recent investigation that could demonstrate an association between *in vivo* and *ex vivo* tau deposition patterns and functional connectivity in a PSP and CBD cohort using [^{18}F]PI-2620 tau-PET, histopathology and fMRI [39]. In the current study, the specificity of tau-PET to DaT-SPECT correlations to connected brain regions was determined by lacking associations between tau burden in the dentate nucleus and striatal DaT availability. In this regard, the dentate nucleus is

known to be affected in later disease stages of PSP [7] and not considered as a part of the dopaminergic system or the basal ganglia pathway, thus providing value as a negative control region. Furthermore, the PCA analysis revealed that condensed tau-PET signals of the dorsal midbrain and the dentate nucleus showed no correlation with the DaT component while the condensed component of tau signals in functionally connected brain regions of the nigrostriatal pathway showed a significant correlation to the DaT component. This supports that tau spreading in 4R-tauopathies occurs within highly connected brain areas [39] where tau accumulation disturbs neuronal function, such as dopamine transmission (Fig. 3).

Earlier studies using the first generation tau tracers [^{18}F]AV-1451 and [^{18}F]THK-5351 as well as a recent study using [^{18}F]PM-PBB3 demonstrated tau-PET signals in PSP patients correlated with clinical severity [40, 41]. Like in our previous investigations, regional [^{18}F]PI-2620 tau-PET signals as well as condensed tau-PET components resulting from the PCA did not correlate with symptom severity measured by the PSP rating scale. Contrary, the DaT component of the PCA showed a significant negative correlation with PSP rating scale scores. This strengthens DaT-SPECT imaging as an index of clinical functionality in 4R-tauopathies while [^{18}F]PI-2620 tau-PET imaging preferably serves as a diagnostic tool. More importantly, residuals of the tau-DaT association correlated with clinical performance measured by PSP rating scale. We note that the PSP rating scale also contains several non-motor items (see Supplementary Table 6), which implies that the observed resilience is not entirely specific to motor function. To address this issue, we expanded our analysis on the group of the patients from Munich by separating PSP rating scale motor items and mentation items as well as adding the MOCA scores as an additional measure of cognitive function. Interestingly, this analysis revealed an even stronger association between the residuals of the tau-DaT association and motor symptoms while there was no association to PSP rating scale mentation items or the MOCA scores. These findings support the emerging concept of motor reserve in analogy to the well studied concept of cognitive reserve in AD research [42–44] which suggests that patients with a high motor reserve are able to sustain motor function despite brain neuropathology in target regions [45]. While the concept of motor reserve is being established in the field of PD and the underlying resilience mechanisms remain poorly understood, our data suggest that this concept may also be applicable to 4R-tauopathies. Patients with a high motor reserve could be identified by combined [^{18}F]PI-2620 tau-PET and DaT-SPECT imaging, facilitating investigation of possible resilience mechanisms.

While pathological aggregation of 4R-tau is thought to be the key feature in 4R-tauopathies, the potentially crucial role of iron dysregulation needs to be kept in mind [46–48].

Subcortical iron accumulation in PSP is well-documented [49–51] and in Parkinsons disease, the excessive iron accumulation in the substantia nigra is suggested to have toxic effects on the dopaminergic neurons, directly interfering with dopamine synthesis and function [48, 52–54]. Therefore, iron accumulation could possibly have a direct or additional influence on the observed effects of DaT-SPECT and PI-2620 Tau-PET associations in our study. Hence, in future imaging studies, the use of additional iron-sensitive MRI scans should be considered when looking at the tau-/DaT interconnection. Generally, further research in this field is needed to elucidate the precise mechanisms by which iron contributes to tau pathology as it would be of great interest to unravel whether iron dysregulation precedes or coincides with tau aggregation and how they possibly exacerbate each other.

For interpretation of the results of this study, the limited sample size of the cohort consisting of 38 clinically diagnosed PSP/CBS patients and 15 clinically diagnosed α -synucleinopathy disease controls that did not receive autopsy confirmation needs to be acknowledged. However, our data build the grounds for future studies with larger cohorts investigating the association between 4R-tau and the dopaminergic system. Furthermore, there is an ongoing debate whether semiquantitative [^{123}I]-Ioflupane SPECT is actually a function of the striatal dopaminergic cell count, i.e. the actual cell loss or if it really reflects axonal dysfunction/DaT density. In a recent study, the postmortem count of substantia nigra pars compacta neurons did not correlate with antemortem DaT binding quantified by DaT-SPECT imaging in 11 confirmed PD cases [55], suggesting that DaT imaging reflects a biomarker of dopaminergic functioning. On the other hand, there is contrary postmortem evidence that reduced striatal [^{123}I]-Ioflupane SPECT signals correlate with reduced density of dopaminergic neurons in the substantia nigra in a cohort of 21 patients (12 PD, 4 AD, 7 DLB) [56]. In accordance, another study revealed that antemortem striatal DaT-SPECT binding correlated with the postmortem neuronal cell count of the SN in a cohort of 6 patients (1 PD, 2 DLB, 1 MSA, 1 AD, 1 Creutzfeldt-Jakob) proposing that DaT imaging is a biomarker for nigrostriatal degeneration [57]. Considering the results of our present study, these inconsistent findings lead to the conclusion that the [^{18}F]PI-2620 tau-PET signal could be either correlated to reduced dopaminergic function or to nigrostriatal cell loss.

Possible off-target binding also needs to be considered as another limitation of this study. As a derivative of AV-1451 which is known to show several off-target binding sites including the basal ganglia or neuromelanin and iron depositions [58, 59], this issue is especially important for PI-2620. Obviously, second generation tau tracers such as PI-2620 were designed explicitly to address this problem and so far PI-2620 has shown very high affinity especially to 4R-tau

with fast washout from cortical and subcortical areas with substantially lower off-target binding to sites like the basal ganglia, choroid plexus, meninges and other sites commonly found in first generation tau tracers [60, 61]. Especially off-target binding in the basal ganglia, mainly caused by binding to monoamine oxidase, in first generation tau-tracers limited their use in 4R-tauopathies [62, 63]. However for PI-2620, several studies [33, 64, 65] could reveal that this issue has been overcome, which makes us confident that the influence of possible off-target binding in this brain region is limited in this study. However, among all second generation tau-PET tracers, [¹⁸F]PI-2620 shows off-target binding to neuromelanin which serves as a possible confounder of PET signals in the substantia nigra [61].

Furthermore, during the disease course of 4R-tauopathies, progressive atrophy in regions like thalamus, midbrain and basal ganglia occurs frequently [66] which could potentially mask the PET signal in these regions. We cannot exclude a possible influence of partial volume effects in this study since we did not have a high resolution 3D T1 MRI data set available for all patients, which in consequence would have further restricted our moderate sample size. Indeed increasing atrophy in target regions like the globus pallidus leading to partial volume effects could produce a decrease in tracer signal, especially in patients with long disease duration. Hence, further studies applying partial volume correction will be needed to address this issue.

In regard to the sometimes rapidly progressing 4R tauopathies PSP and CBS, the relatively long time gap of 3 ± 5 months between DaT and tau imaging also needs to be considered regarding possible limitations of this study as in some cases, disease severity might have progressed between scans.

Conclusions

Our study suggests that the degree of pathological tau accumulation is associated with dopaminergic dysfunction in 4R-tauopathies and supports the concept of tau being a potential driver of neuronal dysfunction and death in 4R-tauopathies. Furthermore, our data imply that besides the effects of tau on the dopaminergic system, resilience factors may have a major influence on symptom severity emphasizing the potential of combined tau-PET and DaT-SPECT imaging in motor reserve research.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00259-024-06637-6>.

Acknowledgements We would like to thank all study participants and their families and care-givers. We also thank cyclotron, radiochemistry and PET imaging crews for their effort.

Author contribution Design: Ferschmann, Brendel, Messerschmidt, Marek, Stephens, Bartenstein, Levin, Höglinger, Sabri, Scheifele; Data acquisition and analysis: Ferschmann, Brendel, Messerschmidt, Gnörich, Marek, Palleis, Katzdobler, Stockbauer, Fietzek, Finze, Biechele, Beyer, Eckenweber, Wall, Saur, Schroeter, Rumpf, Rullmann, Schildan, Patt, Classen, Seibyl, Bartenstein, Höglinger, Sabri, Scheifele; Statistical analysis: Ferschmann, Brendel, Messerschmidt, Scheifele; Drafting and editing of the manuscript as well as revision of the final version of the manuscript: all authors.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability Relevant data generated or analyzed during this study are included in this published article and its supplementary information files. Further datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate The study protocol as well as PET data analyses were approved by the local ethics committee of LMU Munich (application numbers 17–569 and 19–022). All participants provided written informed consent for PET imaging. Patients from Munich are part of the observational study registered at the German Clinical Trials Register (DRKS00016920). The study was carried out according to the principles of the Helsinki Declaration.

Competing interests Christian Ferschmann: none

Konstantin Messerschmidt: reader consultant honorarium from Life Molecular Imaging GmbH, 13353 Berlin, Germany

Johannes Gnörich: reader honorarium from Life Molecular Imaging GmbH, 13353 Berlin, Germany

Henryk Barthel: reader consultant honorarium from Life Molecular Imaging GmbH, 13353 Berlin, Germany

Ken Marek: none

Carla Palleis: none

Sabrina Katzdobler: none

Anna Stockbauer: none

Urban Fietzek: none

Anika Finze: none

Gloria Biechele: none

Leonie Beyer: none

Florian Eckenweber: none

Stephan Wall: none

Dorothee Saur: none

Matthias L. Schroeter: none

Jost-Julian Rumpf: none

Michael Rullmann: none

Andreas Schildan: none

Marianne Patt: none

Andrew Stephens: employee of Life Molecular Imaging

Joseph Classen: none

Peter Bartenstein: none

John Seibyl: none

Nicolai Franzmeier: none

Johannes Levin: reports speaker fees from Bayer Vital, Biogen, Eisai, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent “Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies” (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent “Pharmaceutical Composition and Methods of Use” (EP 22

159 408.8) filed by MODAG GmbH, all activities outside the submitted work

Günter U. Höglinger: none related to this work

Osama Sabri: received research support from Life Molecular Imaging
Matthias Brendel: received speaker honoraria from GE healthcare, Roche and Life Molecular Imaging (LMI) and is an advisor of LMI
Maximilian Scheifele: reader honorarium from Life Molecular Imaging GmbH, 13353 Berlin, Germany

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Sergeant N, Watzek A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration. Tau pathologies with exclusively “Exon10” isoforms. *J Neurochem*. 1999;72:1243–9. <https://doi.org/10.1046/j.1471-4159.1999.0721243.x>.
- Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. *J Neurol*. 1999;246:II6–15. <https://doi.org/10.1007/BF03161076>.
- Buée L, Bussièrè T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Rev*. 2000;33:95–130. [https://doi.org/10.1016/S0165-0173\(00\)00019-9](https://doi.org/10.1016/S0165-0173(00)00019-9).
- Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. *Brain*. 2007;130:1566–76. <https://doi.org/10.1093/brain/awm104>.
- Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. *Brain*. 2011;134:3264–75. <https://doi.org/10.1093/brain/awr234>.
- Ling H, Kovacs GG, Vonsattel JPG, Davey K, Mok KY, Hardy J, et al. Astroglial pathology predominates the earliest stage of corticobasal degeneration pathology. *Brain*. 2016;139:3237–52. <https://doi.org/10.1093/brain/aww256>.
- Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. *Acta Neuropathol*. 2020;140:99–119. <https://doi.org/10.1007/s00401-020-02158-2>.
- Polanco JC, Scicluna BJ, Hill AF, Götz J. Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. *J Biol Chem*. 2016;291:12445–66. <https://doi.org/10.1074/jbc.M115.709485>.
- Wang Y, Balaji V, Kaniyappan S, Krüger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. *Mol Neurodegeneration*. 2017;12:5. <https://doi.org/10.1186/s13024-016-0143-y>.
- Katsinelos T, Zeitler M, Dimou E, Karakatsani A, Müller H-M, Nachman E, et al. Unconventional secretion mediates the trans-cellular spreading of tau. *Cell Rep*. 2018;23:2039–55. <https://doi.org/10.1016/j.celrep.2018.04.056>.
- Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. *Acta Neuropathol*. 2014;127:667–83. <https://doi.org/10.1007/s00401-014-1254-6>.
- Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. *Nat Neurosci*. 2016;19:1085–92. <https://doi.org/10.1038/nn.4328>.
- Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with 18 F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study. *J Nucl Med*. 2020;61:911–9. <https://doi.org/10.2967/jnumed.119.236224>.
- Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. *Neuron*. 2021;109:42–58.e8. <https://doi.org/10.1016/j.neuron.2020.09.042>.
- Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18 F-PI-2620 as a biomarker in progressive supranuclear palsy. *JAMA Neurol*. 2020;77:1408. <https://doi.org/10.1001/jamaneurol.2020.2526>.
- Song M, Beyer L, Kaiser L, Barthel H, van Eimeren T, Marek K, et al. Binding characteristics of [18 F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. *J Cereb Blood Flow Metab*. 2021;41:2957–72. <https://doi.org/10.1177/0271678X211018904>.
- Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann K-T, Rauchmann B-S, et al. 18 F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy. *J Nucl Med*. 2022;63:1754–1760. <https://doi.org/10.2967/jnumed.121.262854>.
- Palleis C, Brendel M, Finze A, Weidinger E, Botzel K, Danek A, et al. Cortical [(18)F]PI-2620 binding differentiates corticobasal syndrome subtypes. *Mov Disord*. 2021;36:2104–15. <https://doi.org/10.1002/mds.28624>.
- Endo H, Tagai K, Ono M, Ikoma Y, Oyama A, Matsuoka K, et al. A machine learning-based approach to discrimination of tauopathies using [18F]PM-PBB3 PET images. *Mov Disord*. 2022;37:2236–46. <https://doi.org/10.1002/mds.29173>.
- Liu F-T, Lu J-Y, Li X-Y, Liang X-N, Jiao F-Y, Ge J-J, et al. 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. *Eur J Nucl Med Mol Imaging*. 2023;50:1395–1405. <https://doi.org/10.1007/s00259-022-06104-0>.
- Booij J, Andringa G, Rijks LJM, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. *Synapse*. 1997;27:183–90. [https://doi.org/10.1002/\(SICI\)1098-2396\(199711\)27:3%3c183::AID-SYN4%3e3.0.CO;2-9](https://doi.org/10.1002/(SICI)1098-2396(199711)27:3%3c183::AID-SYN4%3e3.0.CO;2-9).
- Booij J, Speelman JD, Horstink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic Parkinsonism from those with other forms of Parkinsonism. *Eur J Nucl Med*. 2001;28:266–72. <https://doi.org/10.1007/s002590000460>.
- McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *The Lancet Neurology*. 2007;6:305–13. [https://doi.org/10.1016/S1474-4422\(07\)70057-1](https://doi.org/10.1016/S1474-4422(07)70057-1).
- Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical

- Diagnostic Criteria for PSP. *Mov Disord.* 2017;32:853–64. <https://doi.org/10.1002/mds.26987>.
25. Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, et al. Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. *Eur J Nucl Med Mol Imaging.* 2021;48:3872–85. <https://doi.org/10.1007/s00259-021-05391-3>.
 26. Katzdobler S, Nitschmann A, Barthel H, Bischof G, Beyer L, Marek K, et al. Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies. *Eur J Nucl Med Mol Imaging.* 2023;50(2):423–434. <https://doi.org/10.1007/s00259-022-05964-w>.
 27. Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy bodies. *Mov Disord.* 2020;35:595–605. <https://doi.org/10.1002/mds.27945>.
 28. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology.* 2013;80:496–503. <https://doi.org/10.1212/WNL.0b013e31827f0fd1>.
 29. Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases: PSP diagnostic criteria. *Mov Disord.* 2014;29:1758–66. <https://doi.org/10.1002/mds.26054>.
 30. McMillan CT, Irwin DJ, Nasrallah I, Phillips JS, Spindler M, Rascovsky K, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. *Acta Neuropathol.* 2016;132:935–7. <https://doi.org/10.1007/s00401-016-1640-3>.
 31. Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. *Acta Neuropathol.* 2016;132:931–3. <https://doi.org/10.1007/s00401-016-1618-1>.
 32. Ghirelli A, Tosakulwong N, Weigand SD, Clark HM, Ali F, Botha H, et al. Sensitivity–specificity of tau and amyloid β positron emission tomography in frontotemporal lobar degeneration. *Ann Neurol.* 2020;88:1009–22. <https://doi.org/10.1002/ana.25893>.
 33. Malarte M-L, Gillberg P-G, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains. *Mol Psychiatry.* 2022. <https://doi.org/10.1038/s41380-022-01875-2>.
 34. Li J, Kumar A, Langstrom B, Nordberg A, Agren H. Insight into the binding of first- and second-generation PET tracers to 4R and 3R/4R tau protofibrils. *ACS Chem Neurosci.* 2023;14:3528–39. <https://doi.org/10.1021/acchemneuro.3c00437>.
 35. Liu F-T, Li X-Y, Lu J-Y, Wu P, Li L, Liang X-N, et al. 18F-Florizolotau tau positron emission tomography imaging in patients with multiple system atrophy–Parkinsonian subtype. *Mov Disord.* 2022;37:1915–23. <https://doi.org/10.1002/mds.29159>.
 36. Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B, et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. *Cell Rep.* 2015;11:1176–83. <https://doi.org/10.1016/j.celrep.2015.04.043>.
 37. Boluda S, Iba M, Zhang B, Raible KM, Lee VMY, Trojanowski JQ. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains. *Acta Neuropathol.* 2015;129:221–37. <https://doi.org/10.1007/s00401-014-1373-0>.
 38. Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of cell-to-cell transmission of pathological tau: a review. *JAMA Neurol.* 2019;76:101. <https://doi.org/10.1001/jamaneurol.2018.2505>.
 39. Franzmeier N, Brendel M, Beyer L, Slemann L, Kovacs GG, Arzberger T, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. *Nat Commun.* 2022;13:1362. <https://doi.org/10.1038/s41467-022-28896-3>.
 40. Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy: Tau-pet in progressive supranuclear palsy. *Mov Disord.* 2017;32:124–33. <https://doi.org/10.1002/mds.26834>.
 41. Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, et al. [18F]-THK5351 PET Correlates with topology and symptom severity in progressive supranuclear palsy. *Front Aging Neurosci.* 2018;9:440. <https://doi.org/10.3389/fnagi.2017.00440>.
 42. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. *The Lancet Neurology.* 2012;11:1006–12. [https://doi.org/10.1016/S1474-4422\(12\)70191-6](https://doi.org/10.1016/S1474-4422(12)70191-6).
 43. Soldan A, Pettigrew C, Cai Q, Wang J, Wang M-C, Moghekar A, et al. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer’s disease. *Neurobiol Aging.* 2017;60:164–72. <https://doi.org/10.1016/j.neurobiolaging.2017.09.002>.
 44. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, Belleville S, Cantillon M, Chetelat G, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimers Dement.* 2020;16:1305–11. <https://doi.org/10.1016/j.jalz.2018.07.219>.
 45. Hoening MC, Dzialas V, Drzezga A, van Eimeren T. The concept of motor reserve in Parkinson’s disease: new wine in old bottles? *Mov Disord.* 2022;38:16–20. <https://doi.org/10.1002/mds.29266>.
 46. Kaandstorfer C, Jellinger KA, Eschlbock S, Stefanova N, Weiss G, Wenning GK. The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint. *J Alzheimers Dis.* 2018;61:1253–73. <https://doi.org/10.3233/JAD-170601>.
 47. Lee S, Martinez-Valbuena I, de Andrea CE, Villalba-Esparza M, Ilaalagan S, Couto B, et al. Cell-specific dysregulation of iron and oxygen homeostasis as a novel pathophysiology in PSP. *Ann Neurol.* 2023;93:431–45. <https://doi.org/10.1002/ana.26540>.
 48. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. *Lancet Neurol.* 2014;13:1045–60. [https://doi.org/10.1016/S1474-4422\(14\)70117-6](https://doi.org/10.1016/S1474-4422(14)70117-6).
 49. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson’s Disease Research Group. *Ann Neurol.* 1992;32:94–100. <https://doi.org/10.1002/ana.410320716>.
 50. Lee JH, Lee MS. Brain iron accumulation in atypical Parkinsonian syndromes: in vivo MRI evidences for distinctive patterns. *Front Neurol.* 2019;10:74. <https://doi.org/10.3389/fneur.2019.00074>.
 51. Lee SH, Lyoo CH, Ahn SJ, Rinne JO, Lee MS. Brain regional iron contents in progressive supranuclear palsy. *Parkinsonism Relat Disord.* 2017;45:28–32. <https://doi.org/10.1016/j.parkreldis.2017.09.020>.
 52. Duce JA, Wong BX, Durham H, Devedjian JC, Smith DP, Devos D. Post translational changes to alpha-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. *Mol Neurodegener.* 2017;12:45. <https://doi.org/10.1186/s13024-017-0186-8>.
 53. Han J, Fan Y, Wu P, Huang Z, Li X, Zhao L, et al. Parkinson’s disease dementia: synergistic effects of alpha-synuclein, tau, beta-amyloid, and iron. *Front Aging Neurosci.* 2021;13:743754. <https://doi.org/10.3389/fnagi.2021.743754>.
 54. Wise RM, Wager A, Fietzek UM, Klopstock T, Mosharov EV, Zucca FA, et al. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson’s disease and neurodegeneration with brain iron accumulation disorders. *Neurobiol Dis.* 2022;175:105920. <https://doi.org/10.1016/j.nbd.2022.105920>.

55. Saari L, Kivinen K, Gardberg M, Joutsa J, Nojonen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. *Neurology*. 2017;88:1461–7. <https://doi.org/10.1212/WNL.0000000000003810>.
56. Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. *Brain*. 2012;135:2798–808. <https://doi.org/10.1093/brain/aws211>.
57. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts: correlation of DAT imaging with SN cell counts. *Mov Disord*. 2014;29:1767–73. <https://doi.org/10.1002/mds.25975>.
58. Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, et al. Off-target (18)F-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation. *J Nucl Med*. 2018;59:117–20. <https://doi.org/10.2967/jnumed.117.195248>.
59. Marquie M, Verwer EE, Meltzer AC, Kim SJW, Aguero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. *Acta Neuropathol Commun*. 2017;5:75. <https://doi.org/10.1186/s40478-017-0482-0>.
60. Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. *JAMA Neurol*. 2020;77:1408–19. <https://doi.org/10.1001/jamaneurol.2020.2526>.
61. Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. *Eur J Nucl Med Mol Imaging*. 2019;46:2178–89. <https://doi.org/10.1007/s00259-019-04397-2>.
62. Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppelle R. Tau PET imaging in neurodegenerative disorders. *J Nucl Med*. 2022;63:20S–S26. <https://doi.org/10.2967/jnumed.121.263196>.
63. Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. *Alzheimers Dement (Amst)*. 2018;10:232–6. <https://doi.org/10.1016/j.dadm.2018.01.007>.
64. Kroth H, Oden F, Serra AM, Molette J, Mueller A, Berndt M, et al. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. *Bioorg Med Chem*. 2021;52:116528. <https://doi.org/10.1016/j.bmc.2021.116528>.
65. Kunze G, Kumpfel R, Rullmann M, Barthel H, Brendel M, Patt M, et al. Molecular simulations reveal distinct energetic and kinetic binding properties of [(18)F]PI-2620 on tau filaments from 3R/4R and 4R tauopathies. *ACS Chem Neurosci*. 2022;13:2222–34. <https://doi.org/10.1021/acscchemneuro.2c00291>.
66. McFarland NR. Diagnostic approach to atypical Parkinsonian syndromes. *Continuum (Minneapolis)*. 2016;22:1117–42. <https://doi.org/10.1212/CON.0000000000000348>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Christian Ferschmann¹ · Konstantin Messerschmidt² · Johannes Gnörich¹ · Henryk Barthel² · Ken Marek^{3,4} · Carla Palleis^{5,6,7} · Sabrina Katzdobler⁷ · Anna Stockbauer⁷ · Urban Fietzek⁷ · Anika Finze¹ · Gloria Biechele^{1,8} · Jost-Julian Rumpf⁹ · Dorothee Saur⁹ · Matthias L. Schroeter^{10,11,12} · Michael Rullmann² · Leonie Beyer¹ · Florian Eckenweber¹ · Stephan Wall¹ · Andreas Schildan² · Marianne Patt² · Andrew Stephens¹³ · Joseph Classen⁹ · Peter Bartenstein^{1,5} · John Seibyl^{3,4} · Nicolai Franzmeier^{5,14} · Johannes Levin^{5,6,7} · Günter U. Höglinger^{6,7} · Osama Sabri² · Matthias Brendel^{1,5,6} · Maximilian Scheifele¹ · for the German Imaging Initiative for Tauopathies (GII4T)

✉ Maximilian Scheifele
Maximilian.Scheifele@med.uni-muenchen.de

¹ Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany

² Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

³ InviCRO, LLC, Boston, MA, USA

⁴ Molecular Neuroimaging, A Division of inviCRO, New Haven, CT, USA

⁵ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

⁶ German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

⁷ Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany

⁸ Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany

⁹ Department of Neurology, University Hospital Leipzig, Leipzig, Germany

¹⁰ Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany

¹¹ LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany

¹² Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany

¹³ Life Molecular Imaging GmbH, Berlin, Germany

¹⁴ Institute for Stroke and Dementia Research, LMU University Hospital, LMU Munich, Munich, Germany